GENB (GENB) Stock Price & Analysis
GENB (GENB) rose 3.21% to USD 13.19 as of June 10, 2026 at 12:23 UTC, according to Nexqual real-time market data.
GENB last closed at USD 12.78; the session ranged USD 12.7–13.45 on volume of 610,590 shares. Market capitalization is $1.69B, with a 52-week range of USD 11–16.75 (NMS). Source: Nexqual, June 10, 2026 at 12:23 UTC.
Key Statistics (as of June 10, 2026 at 12:23 UTC)
| Price | USD 13.19 |
|---|---|
| Change | ▲ 3.21% (up) |
| Previous Close | USD 12.78 |
| Open | USD 12.78 |
| Day Range | USD 12.7 – 13.45 |
| 52-Week Range | USD 11 – 16.75 |
| Volume | 610,590 shares |
| Market Cap | $1.69B |
| Exchange | NMS |
Technical Analysis (GENB)
Nexqual's technical model rates GENB "STRONG SELL" based on 0 bullish and 5 bearish signals across 70 daily candles, as of June 10, 2026 at 12:23 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 47.34 (neutral) |
| vs SMA50 | Above (USD 13.18) |
| MACD | -0.12 (negative) |
Analyst Ratings (GENB)
Wall Street analysts rate GENB "None" based on 5 analysts, with a mean price target of USD 25.4 (range USD 22–30), per Nexqual as of June 10, 2026 at 12:23 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 25.4 |
| High Target | USD 30 |
| Low Target | USD 22 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (GENB)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.49 |
| Revenue Estimate | $5.30M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -1.07 vs est -0.49 ▼ miss |
Source: Nexqual, June 10, 2026 at 12:23 UTC.
Financials & Fundamentals (GENB)
| Total Revenue | $30.30M |
|---|---|
| Revenue Growth (YoY) | -18.10% |
| Gross Margin | +0.00% |
| Operating Margin | -887.49% |
| Profit Margin | +0.00% |
| Debt / Equity | 12.74 |
| Current Ratio | 9.17 |
| Total Cash | $516.64M |
| Total Debt | $65.57M |
Source: Nexqual, June 10, 2026 at 12:23 UTC.
Financial Health Score (GENB)
Nexqual rates GENB's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 12:23 UTC.
| Growth | Critical — Revenue -18% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $517M cash vs $66M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$228M |
| Efficiency | Mixed — No data |
Ownership (GENB)
| Insider Ownership | +14.07% |
|---|---|
| Institutional Ownership | +72.00% |
| Shares Outstanding | 128.19M |
| Float | 60.29M |
| Short % of Float | +5.48% |
Source: Nexqual, June 10, 2026 at 12:23 UTC.
Leadership (GENB)
GENB is led by Michael T. Nally (age 49), CEO & Director, per Nexqual as of June 10, 2026 at 12:23 UTC.
| CEO & Director | Michael T. Nally (age 49) |
|---|---|
| President & CFO | Jason E. Silvers (age 53) |
| Co-Founder & CTO | Gevorg Grigoryan (age 44) |
| Chief Scientific Officer | Aarif Khakoo (age 54) |
| Senior Vice President of Discovery Strategy | Daria Hazuda |
Major Backers & Investors (GENB)
Notable institutional backers of GENB include Flagship Pioneering LLC, JPMorgan, FMR, LLC, according to Nexqual as of June 10, 2026 at 12:23 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Flagship Pioneering LLC | 48.89% |
| JPMorgan | 3.62% |
| FMR, LLC | 3.29% |
| Capital Group | 3.12% |
| SmallCap World Fund Inc | 2.85% |
| Braidwell LP | 2.8% |
| Price (T.Rowe) Associates Inc | 1.65% |
| Arch Venture Management, Llc | 1.52% |
Source: Nexqual, June 10, 2026 at 12:23 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| EIKN | Eikon Therapeutics, Inc. | USD 8.77 | ▼ 2.12% |
| MANE | Veradermics, Incorporated | USD 95.91 | ▲ 4.6% |
| KLRA | Kailera Therapeutics, Inc. | USD 19.64 | ▲ 1.39% |
| XNDU | Xanadu Quantum Technologies Lim | USD 12 | ▼ 6.98% |
| ALMU | Aeluma, Inc. | USD 22.56 | ▼ 0.13% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 12:23 UTC. This page is informational and not investment advice.